0

Close
 
Upcoming Allied Market Research
2023
Pharmaceutical Suspension Market

Pharmaceutical Suspension Market

by Type (Oral Suspension, Parenteral Suspension), by Proportion of Solid Particles (Dilute Suspension (2 to 10% w/v solid), Concentrated Suspension (50% w/v solid)), by Electrokinetic Nature (Flocculated Suspension, Deflocculated Suspension), by Size of Solid Particles (Colloidal Suspension ( Less than 1 micron), Coarse Suspension (and1 micron), Nano Suspension (10 nanograms)) and by End User (Hospitals, Home Care Settings, Clinics, Diagnostic Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12351
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pharmaceutical Suspension Market

Request Now !

A pharmaceutical suspension is a dispersion of insoluble particles in a liquid medium. Pharmaceutical suspensions form a crucial class of pharmaceutical dosage forms. Various advantages of pharmaceutical suspensions include effective dispensing of different hydrophobic drugs, masking unpleasant taste of some ingredients, offering resistance to drug degradation due to oxidation, hydrolysis or microbial activity, efficient intramuscular depot therapy, and easy swallowing for pediatric and geriatric patients. In addition, pharmaceutical suspensions can incorporate a higher concentration of drugs than solution dosage forms.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

However, with COVID-19 the supply chain of raw materials required to manufacture pharmaceutical suspensions has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining, as manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the pharmaceutical suspension market.

Top Impacting Factors

Suspensions are usually made with the drugs such as prednisolone that are insoluble or poorly soluble in aqueous solutions. This helps them get properly delivered to the target site. Suspensions can help with the absorption of such drugs, which is a key factor positively influencing the growth of the market.

Suspensions can be used for a topical application. This is the case with the calamine solutions. With a rise in cases with dermatological issues, the use of calamine lotions has increased. Therefore, this factor has further contributed toward the growth of the pharmaceutical suspension market.

In addition, pharmaceutical suspensions are prepared to mask the unpleasant or bitter taste of drugs. Drugs formulated in suspensions are more palatable. With this, pediatricians can easily prescribe drugs to children. Hence, this factor is augmenting the growth of the pharmaceutical suspension market.

However, the formulation of pharmaceutical suspensions is bulky and difficult to formulate. In addition, sedimentation of suspensions can occur while handling. These factors together impede the growth of the pharmaceutical suspension market.

Key Market Trends

The hospital segment is anticipated to garner a large share in the pharmaceutical suspension market, owing to the significant number of inpatient and outpatient visits and the requirement of a large volume of drugs, which often include pharmaceutical suspensions to cater during the treatment process.

North America is expected to lead the pharmaceutical suspension market. This can be attributed to the region's rising prevalence of chronic diseases and the presence of key players in the pharmaceutical suspension market.

Key players of the global pharmaceutical suspension market are focusing on extending their product portfolios and increasing the number of their pharmaceutical suspension manufacturing facilities.

Asia Pacific is expected to hold a major share of the pharmaceutical suspension market during the forecast period, owing to increasing number of pediatric patients who are often being prescribed syrups in the form of suspensions.

Key Benefits of the Report

  • This study presents the analytical depiction of the pharmaceutical suspension industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Pharmaceutical Suspension Report

  • Which are the leading players active in the pharmaceutical suspension market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the pharmaceutical suspension market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps in the market?
  • What are the impacts of COVID-19 on the industry?
  • What is pharmaceutical suspension?
  • What are the current and predicted trends of the market?

 Pharmaceutical Suspension Market Report Highlights

Aspects Details
By Type
  • Oral Suspension
  • Parenteral Suspension
By Proportion of Solid Particles
  • Dilute Suspension (2 to 10% w/v solid)
  • Concentrated Suspension (50% w/v solid)
By Electrokinetic Nature
  • Flocculated Suspension
  • Deflocculated Suspension
By Size of Solid Particles
  • Colloidal Suspension (< 1 micron)
  • Coarse Suspension (>1 micron)
  • Nano Suspension (10 nanograms)
By End User
  • Hospitals
  • Home Care Settings
  • Clinics
  • Diagnostic Centers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players 3M Company, Becton, Dickinson and Company, Novartis AG, Bayer AG, Pfizer, Inc., Johnson and Johnson, Inc., Antares Pharma, Inc. , F. Hoffman-La Roche, Merck and Co., Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Oral Suspension

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Parenteral Suspension

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY PROPORTION OF SOLID PARTICLES

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Proportion Of Solid Particles

    • 5.2. Dilute Suspension (2 To 10% W/v Solid)

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Concentrated Suspension (50% W/v Solid)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY ELECTROKINETIC NATURE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Electrokinetic Nature

    • 6.2. Flocculated Suspension

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Deflocculated Suspension

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY SIZE OF SOLID PARTICLES

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Size Of Solid Particles

    • 7.2. Colloidal Suspension ( Less Than 1 Micron)

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Coarse Suspension (and1 Micron)

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Nano Suspension (10 Nanograms)

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY END USER

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By End User

    • 8.2. Hospitals

      • 8.2.1. Key Market Trends, Growth Factors and Opportunities

      • 8.2.2. Market Size and Forecast, By Region

      • 8.2.3. Market Share Analysis, By Country

    • 8.3. Home Care Settings

      • 8.3.1. Key Market Trends, Growth Factors and Opportunities

      • 8.3.2. Market Size and Forecast, By Region

      • 8.3.3. Market Share Analysis, By Country

    • 8.4. Clinics

      • 8.4.1. Key Market Trends, Growth Factors and Opportunities

      • 8.4.2. Market Size and Forecast, By Region

      • 8.4.3. Market Share Analysis, By Country

    • 8.5. Diagnostic Centers

      • 8.5.1. Key Market Trends, Growth Factors and Opportunities

      • 8.5.2. Market Size and Forecast, By Region

      • 8.5.3. Market Share Analysis, By Country

  • CHAPTER 9: PHARMACEUTICAL SUSPENSION MARKET, BY REGION

    • 9.1. Market Overview

      • 9.1.1 Market Size and Forecast, By Region

    • 9.2. North America

      • 9.2.1. Key Market Trends and Opportunities

      • 9.2.2. Market Size and Forecast, By Type

      • 9.2.3. Market Size and Forecast, By Proportion Of Solid Particles

      • 9.2.4. Market Size and Forecast, By Electrokinetic Nature

      • 9.2.5. Market Size and Forecast, By Size Of Solid Particles

      • 9.2.6. Market Size and Forecast, By End User

      • 9.2.7. Market Size and Forecast, By Country

      • 9.2.8. U.S. Pharmaceutical Suspension Market

        • 9.2.8.1. Market Size and Forecast, By Type
        • 9.2.8.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.2.8.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.2.8.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.2.8.5. Market Size and Forecast, By End User

      • 9.2.9. Canada Pharmaceutical Suspension Market

        • 9.2.9.1. Market Size and Forecast, By Type
        • 9.2.9.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.2.9.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.2.9.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.2.9.5. Market Size and Forecast, By End User

      • 9.2.10. Mexico Pharmaceutical Suspension Market

        • 9.2.10.1. Market Size and Forecast, By Type
        • 9.2.10.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.2.10.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.2.10.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.2.10.5. Market Size and Forecast, By End User

    • 9.3. Europe

      • 9.3.1. Key Market Trends and Opportunities

      • 9.3.2. Market Size and Forecast, By Type

      • 9.3.3. Market Size and Forecast, By Proportion Of Solid Particles

      • 9.3.4. Market Size and Forecast, By Electrokinetic Nature

      • 9.3.5. Market Size and Forecast, By Size Of Solid Particles

      • 9.3.6. Market Size and Forecast, By End User

      • 9.3.7. Market Size and Forecast, By Country

      • 9.3.8. France Pharmaceutical Suspension Market

        • 9.3.8.1. Market Size and Forecast, By Type
        • 9.3.8.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.8.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.8.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.8.5. Market Size and Forecast, By End User

      • 9.3.9. Germany Pharmaceutical Suspension Market

        • 9.3.9.1. Market Size and Forecast, By Type
        • 9.3.9.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.9.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.9.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.9.5. Market Size and Forecast, By End User

      • 9.3.10. Italy Pharmaceutical Suspension Market

        • 9.3.10.1. Market Size and Forecast, By Type
        • 9.3.10.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.10.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.10.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.10.5. Market Size and Forecast, By End User

      • 9.3.11. Spain Pharmaceutical Suspension Market

        • 9.3.11.1. Market Size and Forecast, By Type
        • 9.3.11.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.11.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.11.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.11.5. Market Size and Forecast, By End User

      • 9.3.12. UK Pharmaceutical Suspension Market

        • 9.3.12.1. Market Size and Forecast, By Type
        • 9.3.12.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.12.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.12.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.12.5. Market Size and Forecast, By End User

      • 9.3.13. Russia Pharmaceutical Suspension Market

        • 9.3.13.1. Market Size and Forecast, By Type
        • 9.3.13.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.13.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.13.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.13.5. Market Size and Forecast, By End User

      • 9.3.14. Rest Of Europe Pharmaceutical Suspension Market

        • 9.3.14.1. Market Size and Forecast, By Type
        • 9.3.14.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.3.14.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.3.14.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.3.14.5. Market Size and Forecast, By End User

    • 9.4. Asia-Pacific

      • 9.4.1. Key Market Trends and Opportunities

      • 9.4.2. Market Size and Forecast, By Type

      • 9.4.3. Market Size and Forecast, By Proportion Of Solid Particles

      • 9.4.4. Market Size and Forecast, By Electrokinetic Nature

      • 9.4.5. Market Size and Forecast, By Size Of Solid Particles

      • 9.4.6. Market Size and Forecast, By End User

      • 9.4.7. Market Size and Forecast, By Country

      • 9.4.8. China Pharmaceutical Suspension Market

        • 9.4.8.1. Market Size and Forecast, By Type
        • 9.4.8.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.8.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.8.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.8.5. Market Size and Forecast, By End User

      • 9.4.9. Japan Pharmaceutical Suspension Market

        • 9.4.9.1. Market Size and Forecast, By Type
        • 9.4.9.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.9.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.9.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.9.5. Market Size and Forecast, By End User

      • 9.4.10. India Pharmaceutical Suspension Market

        • 9.4.10.1. Market Size and Forecast, By Type
        • 9.4.10.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.10.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.10.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.10.5. Market Size and Forecast, By End User

      • 9.4.11. South Korea Pharmaceutical Suspension Market

        • 9.4.11.1. Market Size and Forecast, By Type
        • 9.4.11.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.11.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.11.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.11.5. Market Size and Forecast, By End User

      • 9.4.12. Australia Pharmaceutical Suspension Market

        • 9.4.12.1. Market Size and Forecast, By Type
        • 9.4.12.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.12.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.12.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.12.5. Market Size and Forecast, By End User

      • 9.4.13. Thailand Pharmaceutical Suspension Market

        • 9.4.13.1. Market Size and Forecast, By Type
        • 9.4.13.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.13.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.13.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.13.5. Market Size and Forecast, By End User

      • 9.4.14. Malaysia Pharmaceutical Suspension Market

        • 9.4.14.1. Market Size and Forecast, By Type
        • 9.4.14.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.14.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.14.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.14.5. Market Size and Forecast, By End User

      • 9.4.15. Indonesia Pharmaceutical Suspension Market

        • 9.4.15.1. Market Size and Forecast, By Type
        • 9.4.15.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.15.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.15.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.15.5. Market Size and Forecast, By End User

      • 9.4.16. Rest of Asia Pacific Pharmaceutical Suspension Market

        • 9.4.16.1. Market Size and Forecast, By Type
        • 9.4.16.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.4.16.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.4.16.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.4.16.5. Market Size and Forecast, By End User

    • 9.5. LAMEA

      • 9.5.1. Key Market Trends and Opportunities

      • 9.5.2. Market Size and Forecast, By Type

      • 9.5.3. Market Size and Forecast, By Proportion Of Solid Particles

      • 9.5.4. Market Size and Forecast, By Electrokinetic Nature

      • 9.5.5. Market Size and Forecast, By Size Of Solid Particles

      • 9.5.6. Market Size and Forecast, By End User

      • 9.5.7. Market Size and Forecast, By Country

      • 9.5.8. Brazil Pharmaceutical Suspension Market

        • 9.5.8.1. Market Size and Forecast, By Type
        • 9.5.8.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.5.8.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.5.8.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.5.8.5. Market Size and Forecast, By End User

      • 9.5.9. South Africa Pharmaceutical Suspension Market

        • 9.5.9.1. Market Size and Forecast, By Type
        • 9.5.9.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.5.9.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.5.9.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.5.9.5. Market Size and Forecast, By End User

      • 9.5.10. Saudi Arabia Pharmaceutical Suspension Market

        • 9.5.10.1. Market Size and Forecast, By Type
        • 9.5.10.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.5.10.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.5.10.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.5.10.5. Market Size and Forecast, By End User

      • 9.5.11. UAE Pharmaceutical Suspension Market

        • 9.5.11.1. Market Size and Forecast, By Type
        • 9.5.11.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.5.11.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.5.11.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.5.11.5. Market Size and Forecast, By End User

      • 9.5.12. Argentina Pharmaceutical Suspension Market

        • 9.5.12.1. Market Size and Forecast, By Type
        • 9.5.12.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.5.12.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.5.12.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.5.12.5. Market Size and Forecast, By End User

      • 9.5.13. Rest of LAMEA Pharmaceutical Suspension Market

        • 9.5.13.1. Market Size and Forecast, By Type
        • 9.5.13.2. Market Size and Forecast, By Proportion Of Solid Particles
        • 9.5.13.3. Market Size and Forecast, By Electrokinetic Nature
        • 9.5.13.4. Market Size and Forecast, By Size Of Solid Particles
        • 9.5.13.5. Market Size and Forecast, By End User

  • CHAPTER 10: COMPETITIVE LANDSCAPE

    • 10.1. Introduction

    • 10.2. Top Winning Strategies

    • 10.3. Product Mapping Of Top 10 Player

    • 10.4. Competitive Dashboard

    • 10.5. Competitive Heatmap

    • 10.6. Top Player Positioning,2022

  • CHAPTER 11: COMPANY PROFILES

    • 11.1. Johnson And Johnson, Inc.

      • 11.1.1. Company Overview

      • 11.1.2. Key Executives

      • 11.1.3. Company Snapshot

      • 11.1.4. Operating Business Segments

      • 11.1.5. Product Portfolio

      • 11.1.6. Business Performance

      • 11.1.7. Key Strategic Moves and Developments

    • 11.2. F. Hoffman-La Roche

      • 11.2.1. Company Overview

      • 11.2.2. Key Executives

      • 11.2.3. Company Snapshot

      • 11.2.4. Operating Business Segments

      • 11.2.5. Product Portfolio

      • 11.2.6. Business Performance

      • 11.2.7. Key Strategic Moves and Developments

    • 11.3. Merck And Co., Inc.

      • 11.3.1. Company Overview

      • 11.3.2. Key Executives

      • 11.3.3. Company Snapshot

      • 11.3.4. Operating Business Segments

      • 11.3.5. Product Portfolio

      • 11.3.6. Business Performance

      • 11.3.7. Key Strategic Moves and Developments

    • 11.4. Bayer AG, Pfizer, Inc.

      • 11.4.1. Company Overview

      • 11.4.2. Key Executives

      • 11.4.3. Company Snapshot

      • 11.4.4. Operating Business Segments

      • 11.4.5. Product Portfolio

      • 11.4.6. Business Performance

      • 11.4.7. Key Strategic Moves and Developments

    • 11.5. Novartis AG

      • 11.5.1. Company Overview

      • 11.5.2. Key Executives

      • 11.5.3. Company Snapshot

      • 11.5.4. Operating Business Segments

      • 11.5.5. Product Portfolio

      • 11.5.6. Business Performance

      • 11.5.7. Key Strategic Moves and Developments

    • 11.6. 3M Company

      • 11.6.1. Company Overview

      • 11.6.2. Key Executives

      • 11.6.3. Company Snapshot

      • 11.6.4. Operating Business Segments

      • 11.6.5. Product Portfolio

      • 11.6.6. Business Performance

      • 11.6.7. Key Strategic Moves and Developments

    • 11.7. Becton, Dickinson And Company

      • 11.7.1. Company Overview

      • 11.7.2. Key Executives

      • 11.7.3. Company Snapshot

      • 11.7.4. Operating Business Segments

      • 11.7.5. Product Portfolio

      • 11.7.6. Business Performance

      • 11.7.7. Key Strategic Moves and Developments

    • 11.8. GlaxoSmithKline Plc

      • 11.8.1. Company Overview

      • 11.8.2. Key Executives

      • 11.8.3. Company Snapshot

      • 11.8.4. Operating Business Segments

      • 11.8.5. Product Portfolio

      • 11.8.6. Business Performance

      • 11.8.7. Key Strategic Moves and Developments

    • 11.9. Antares Pharma, Inc. 

      • 11.9.1. Company Overview

      • 11.9.2. Key Executives

      • 11.9.3. Company Snapshot

      • 11.9.4. Operating Business Segments

      • 11.9.5. Product Portfolio

      • 11.9.6. Business Performance

      • 11.9.7. Key Strategic Moves and Developments

    • 11.10. Glenmark Pharmaceuticals Ltd

      • 11.10.1. Company Overview

      • 11.10.2. Key Executives

      • 11.10.3. Company Snapshot

      • 11.10.4. Operating Business Segments

      • 11.10.5. Product Portfolio

      • 11.10.6. Business Performance

      • 11.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR ORAL SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR DILUTE SUSPENSION (2 TO 10% W/V SOLID), BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR CONCENTRATED SUSPENSION (50% W/V SOLID), BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR FLOCCULATED SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR DEFLOCCULATED SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR COLLOIDAL SUSPENSION ( LESS THAN 1 MICRON), BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR COARSE SUSPENSION (AND1 MICRON), BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR NANO SUSPENSION (10 NANOGRAMS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL SUSPENSION MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA PHARMACEUTICAL SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. U.S. PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 28. U.S. PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 29. U.S. PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 30. U.S. PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. CANADA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 33. CANADA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 34. CANADA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 35. CANADA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 39. MEXICO PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE PHARMACEUTICAL SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 46. EUROPE PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 50. FRANCE PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 51. FRANCE PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. GERMANY PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. GERMANY PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 54. GERMANY PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 55. GERMANY PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 56. GERMANY PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. ITALY PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ITALY PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 59. ITALY PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 60. ITALY PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 61. ITALY PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. SPAIN PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. SPAIN PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 64. SPAIN PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 65. SPAIN PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 66. SPAIN PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. UK PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. UK PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 69. UK PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 70. UK PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 71. UK PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. RUSSIA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 73. RUSSIA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 74. RUSSIA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 75. RUSSIA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 76. RUSSIA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. REST OF EUROPE PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. REST OF EUROPE PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 79. REST OF EUROPE PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 80. REST OF EUROPE PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 81. REST OF EUROPE PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 83. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 86. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 87. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. CHINA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 89. CHINA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 90. CHINA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 91. CHINA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 92. CHINA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. JAPAN PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 94. JAPAN PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 95. JAPAN PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 96. JAPAN PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 97. JAPAN PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. INDIA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 99. INDIA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 100. INDIA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 101. INDIA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 102. INDIA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH KOREA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 104. SOUTH KOREA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 105. SOUTH KOREA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH KOREA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 107. SOUTH KOREA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. AUSTRALIA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 109. AUSTRALIA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 110. AUSTRALIA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 111. AUSTRALIA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 112. AUSTRALIA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 113. THAILAND PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 114. THAILAND PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 115. THAILAND PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 116. THAILAND PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 117. THAILAND PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 118. MALAYSIA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 119. MALAYSIA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 120. MALAYSIA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 121. MALAYSIA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 122. MALAYSIA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 123. INDONESIA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 124. INDONESIA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 125. INDONESIA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 126. INDONESIA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 127. INDONESIA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 128. REST OF ASIA PACIFIC PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 129. REST OF ASIA PACIFIC PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 130. REST OF ASIA PACIFIC PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 131. REST OF ASIA PACIFIC PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 132. REST OF ASIA PACIFIC PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 133. LAMEA PHARMACEUTICAL SUSPENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 134. LAMEA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 135. LAMEA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 136. LAMEA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 137. LAMEA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 138. LAMEA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 139. BRAZIL PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 140. BRAZIL PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 141. BRAZIL PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 142. BRAZIL PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 143. BRAZIL PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 144. SOUTH AFRICA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 145. SOUTH AFRICA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 146. SOUTH AFRICA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 147. SOUTH AFRICA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 148. SOUTH AFRICA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 149. SAUDI ARABIA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 150. SAUDI ARABIA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 151. SAUDI ARABIA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 152. SAUDI ARABIA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 153. SAUDI ARABIA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 154. UAE PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 155. UAE PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 156. UAE PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 157. UAE PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 158. UAE PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 159. ARGENTINA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 160. ARGENTINA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 161. ARGENTINA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 162. ARGENTINA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 163. ARGENTINA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 164. REST OF LAMEA PHARMACEUTICAL SUSPENSION, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 165. REST OF LAMEA PHARMACEUTICAL SUSPENSION, BY PROPORTION OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 166. REST OF LAMEA PHARMACEUTICAL SUSPENSION, BY ELECTROKINETIC NATURE, 2022-2032 ($MILLION)
  • TABLE 167. REST OF LAMEA PHARMACEUTICAL SUSPENSION, BY SIZE OF SOLID PARTICLES, 2022-2032 ($MILLION)
  • TABLE 168. REST OF LAMEA PHARMACEUTICAL SUSPENSION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 169. JOHNSON AND JOHNSON, INC.: KEY EXECUTIVES
  • TABLE 170. JOHNSON AND JOHNSON, INC.: COMPANY SNAPSHOT
  • TABLE 171. JOHNSON AND JOHNSON, INC.: OPERATING SEGMENTS
  • TABLE 172. JOHNSON AND JOHNSON, INC.: PRODUCT PORTFOLIO
  • TABLE 173. JOHNSON AND JOHNSON, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174. F. HOFFMAN-LA ROCHE: KEY EXECUTIVES
  • TABLE 175. F. HOFFMAN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 176. F. HOFFMAN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 177. F. HOFFMAN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 178. F. HOFFMAN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 179. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 180. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 181. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 182. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 183. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 184. BAYER AG, PFIZER, INC.: KEY EXECUTIVES
  • TABLE 185. BAYER AG, PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 186. BAYER AG, PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 187. BAYER AG, PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 188. BAYER AG, PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 190. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 191. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 192. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 193. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 194. 3M COMPANY: KEY EXECUTIVES
  • TABLE 195. 3M COMPANY: COMPANY SNAPSHOT
  • TABLE 196. 3M COMPANY: OPERATING SEGMENTS
  • TABLE 197. 3M COMPANY: PRODUCT PORTFOLIO
  • TABLE 198. 3M COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 199. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 200. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 201. BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
  • TABLE 202. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 203. BECTON, DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 204. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 205. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 206. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 207. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 208. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 209. ANTARES PHARMA, INC. : KEY EXECUTIVES
  • TABLE 210. ANTARES PHARMA, INC. : COMPANY SNAPSHOT
  • TABLE 211. ANTARES PHARMA, INC. : OPERATING SEGMENTS
  • TABLE 212. ANTARES PHARMA, INC. : PRODUCT PORTFOLIO
  • TABLE 213. ANTARES PHARMA, INC. : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 214. GLENMARK PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 215. GLENMARK PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 216. GLENMARK PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 217. GLENMARK PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 218. GLENMARK PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL SUSPENSION MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 3. SEGMENTATION PHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 11. PHARMACEUTICAL SUSPENSION MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. PHARMACEUTICAL SUSPENSION MARKET FOR ORAL SUSPENSION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL SUSPENSION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. PHARMACEUTICAL SUSPENSION MARKET SEGMENTATION, BY BY PROPORTION OF SOLID PARTICLES
  • FIGURE 15. PHARMACEUTICAL SUSPENSION MARKET FOR DILUTE SUSPENSION (2 TO 10% W/V SOLID), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. PHARMACEUTICAL SUSPENSION MARKET FOR CONCENTRATED SUSPENSION (50% W/V SOLID), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. PHARMACEUTICAL SUSPENSION MARKET SEGMENTATION, BY BY ELECTROKINETIC NATURE
  • FIGURE 18. PHARMACEUTICAL SUSPENSION MARKET FOR FLOCCULATED SUSPENSION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. PHARMACEUTICAL SUSPENSION MARKET FOR DEFLOCCULATED SUSPENSION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. PHARMACEUTICAL SUSPENSION MARKET SEGMENTATION, BY BY SIZE OF SOLID PARTICLES
  • FIGURE 21. PHARMACEUTICAL SUSPENSION MARKET FOR COLLOIDAL SUSPENSION ( LESS THAN 1 MICRON), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. PHARMACEUTICAL SUSPENSION MARKET FOR COARSE SUSPENSION (AND1 MICRON), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. PHARMACEUTICAL SUSPENSION MARKET FOR NANO SUSPENSION (10 NANOGRAMS), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. PHARMACEUTICAL SUSPENSION MARKET SEGMENTATION, BY BY END USER
  • FIGURE 25. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. PHARMACEUTICAL SUSPENSION MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. PHARMACEUTICAL SUSPENSION MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: PHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. JOHNSON AND JOHNSON, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. JOHNSON AND JOHNSON, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. JOHNSON AND JOHNSON, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. F. HOFFMAN-LA ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. F. HOFFMAN-LA ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. F. HOFFMAN-LA ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. BAYER AG, PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. BAYER AG, PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. BAYER AG, PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. 3M COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. 3M COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. 3M COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. BECTON, DICKINSON AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. ANTARES PHARMA, INC. : NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. ANTARES PHARMA, INC. : REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. ANTARES PHARMA, INC. : REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. GLENMARK PHARMACEUTICALS LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. GLENMARK PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. GLENMARK PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Pharmaceutical Suspension Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers